Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35617521.
- Also identified by DOI 10.1158/1078-0432.CCR-22-1083 and PMC identifier 9357115.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The patient-derived organoids (PDO) platform recapitulates the phenotype, genotype, and molecular characteristics of primary tumors. High-throughput drug screening in terms of pharmacotyping using standard-of-care chemotherapy agents in the PDO platform has shown promising sensitivities to guide precision medicine for individual patients with pancreatic ductal adenocarcinoma (PDAC) within a clinically relevant time frame. See related article by Seppälä et al., p. 3296.
Medical subject headings
- Carcinoma, Pancreatic Ductal
- Pancreatic Neoplasms